| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Brivudine (INN); Zostex (TN) | ||||||||||
| Abbr | BVDU | ||||||||||
| Formula | C11H13BrN2O5 | ||||||||||
| Exact mass | 332.0008 | ||||||||||
| Mol weight | 333.1353 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Antiviral DG02840 Anti-herpesvirus agent | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiviral, DNA polymerase inhibitor | ||||||||||
| Target | HSV1 DNA polymerase [KO:K18964] | ||||||||||
| Pathway |
| ||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors J05AB15 Brivudine D07249 Brivudine (INN) Drug groups [BR:br08330] Antiviral DG02840 Anti-herpesvirus agent D07249 Brivudine Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor Herpesvirus DNA polymerase inhibitor D07249 Brivudine (INN) Antimicrobials abbreviations [BR:br08327] Antivirals Genome replication inhibitor Herpesvirus DNA polymerase inhibitor D07249 Brivudine (INN) | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 19 1 C1y C 18.3598 -17.8020 2 N4y N 19.6949 -17.3769 3 O2x O 17.2390 -16.8913 4 C1x C 17.9395 -19.0630 5 C8y C 20.8963 -17.9831 6 C8x C 19.6804 -15.9482 7 C1y C 16.1181 -17.7320 8 C1y C 16.5384 -19.0630 9 N4x N 22.1122 -17.2976 10 O5x O 20.9093 -19.3974 11 C8y C 20.8819 -15.1941 12 C1b C 14.7871 -17.3117 13 C8y C 22.0978 -15.8688 14 C2b C 20.8689 -13.7798 15 O1a O 13.7363 -18.2924 16 O5x O 23.2307 -15.1292 17 C2b C 22.0148 -13.0943 18 X Br 22.0033 -11.6944 19 O1a O 15.6978 -20.1839 BOND 20 1 2 5 1 2 2 6 1 3 3 7 1 4 4 8 1 5 5 9 1 6 5 10 2 7 6 11 2 8 7 12 1 #Up 9 9 13 1 10 11 14 1 11 12 15 1 12 13 16 2 13 7 8 1 14 11 13 1 15 14 17 2 16 1 2 1 #Up 17 17 18 1 18 1 3 1 19 1 4 1 20 8 19 1 #Down |